Allogene Therapeutics Inc (NASDAQ:ALLO) shares traded 3.31% higher at $2.81 on Wall Street last session.
In accordance with the data, 16 analysts cover Allogene Therapeutics Inc (NASDAQ:ALLO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $4.50, we find $12.00. Given the previous closing price of $2.72, this indicates a potential upside of 341.18 percent. ALLO stock price is now -12.47% away from the 50-day moving average and -42.02% away from the 200-day moving average. The market capitalization of the company currently stands at $472.87M.
It has been rated a hold by 3 analysts and a buy by 12. Brokers who have rated the stock have averaged $13.23 as their price target over the next twelve months.
In other news, Mayo Stephen, Director sold 10,000 shares of the company’s stock on Aug 07. The stock was sold for $42,855 at an average price of $4.29. Upon completion of the transaction, the Director now directly owns 25,328 shares in the company, valued at $71171.68. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 13, General Counsel Bhavnagri Veer sold 3,000 shares of the business’s stock. A total of $20,550 was realized by selling the stock at an average price of $6.85. This leaves the insider owning 577,677 shares of the company worth $1.62 million. Insiders disposed of 111,800 shares of company stock worth roughly $0.31 million over the past 1 year. A total of 37.18% of the company’s stock is owned by insiders.
Allogene Therapeutics Inc (NASDAQ: ALLO) opened at $2.7000 on Thursday. During the past 12 months, Allogene Therapeutics Inc has had a low of $2.31 and a high of $11.10. As of last week, the company has a debt-to-equity ratio of 0.17, a current ratio of 12.58, and a quick ratio of 12.58. The fifty day moving average price for ALLO is $3.2104 and a two-hundred day moving average price translates $4.8467 for the stock.
The latest earnings results from Allogene Therapeutics Inc (NASDAQ: ALLO) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.37, beating analysts’ expectations of -$0.52 by 0.15. This compares to -$0.58 EPS in the same period last year. The net profit margin was -178954.30% and return on equity was -50.32% for ALLO. The company reported revenue of $43000.0 for the quarter, compared to $49000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -12.24 percent. For the current quarter, analysts expect ALLO to generate $10k in revenue.
Allogene Therapeutics Inc(ALLO) Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
